Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma.

Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO.

Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1069-74.

2.
3.

Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P.

Ward PE, Chow A, Drapeau G.

Biochem Pharmacol. 1991 Jul 25;42(4):721-7.

PMID:
1651078
4.

Metabolism of bradykinin analogs by angiotensin I converting enzyme and carboxypeptidase N.

Drapeau G, Chow A, Ward PE.

Peptides. 1991 May-Jun;12(3):631-8.

PMID:
1656406
5.

Possible involvement of placental proteases in bradykinin (BK) degradation.

Kuno N, Mizutani S, Ohno Y, Goto K, Itakura A, Kondo I, Kurauchi O, Kikkawa F, Tomoda Y.

Reprod Fertil Dev. 1997;9(6):633-9.

PMID:
9551668
6.

Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study.

Blais C Jr, Drapeau G, Raymond P, Lamontagne D, Gervais N, Venneman I, Adam A.

Am J Physiol. 1997 Nov;273(5 Pt 2):H2263-71.

7.

Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.

Sivieri DO Jr, Bispo-da-Silva LB, Oliveira EB, Resende AC, Salgado MC.

Hypertension. 2007 Jul;50(1):110-5. Epub 2007 Apr 30.

9.

Contributions of various rat plasma peptidases to kinin hydrolysis.

Ishida H, Scicli AG, Carretero OA.

J Pharmacol Exp Ther. 1989 Dec;251(3):817-20.

PMID:
2557417
10.

Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats.

Stanziola L, Greene LJ, Santos RA.

Am J Hypertens. 1999 Oct;12(10 Pt 1):1021-9.

PMID:
10560789
11.

Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart.

Ahmad M, Zeitlin IJ, Parratt JR, Pitt AR.

Arch Pharm Res. 2006 Mar;29(3):241-8.

PMID:
16596998
12.

Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation.

Molinaro G, Adam A, Lepage Y, Hammerschmidt D, Koenigbauer U, Eastlund T.

Transfusion. 2002 Nov;42(11):1458-65.

PMID:
12421219
13.

Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma.

Cyr M, Lepage Y, Blais C Jr, Gervais N, Cugno M, Rouleau JL, Adam A.

Am J Physiol Heart Circ Physiol. 2001 Jul;281(1):H275-83.

14.

Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P.

Blais C Jr, Marc-Aurèle J, Simmons WH, Loute G, Thibault P, Skidgel RA, Adam A.

Peptides. 1999;20(4):421-30.

PMID:
10458510
15.
16.

Degradation of bradykinin in semen of ram and boar.

Boettger A, Kertscher U, Steinmann C, Baeger U, Siems WE, Heder G.

Biochem Pharmacol. 1993 May 25;45(10):1983-8.

PMID:
8390257
17.

The release of kininase from rat isolated hearts during myocardial ischaemia.

Ahmad M, Zeitlin IJ, Parratt JR.

Immunopharmacology. 1996 Jun;33(1-3):299-300.

PMID:
8856168
18.
19.

Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema.

Blais C Jr, Rouleau JL, Brown NJ, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A.

Immunopharmacology. 1999 Sep;43(2-3):293-302.

PMID:
10596866
20.

Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.

Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V.

Circ Res. 2003 Jul 25;93(2):148-54. Epub 2003 Jun 12.

Supplemental Content

Support Center